Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma ; volume:9 ; number:1 ; day:12 ; month:1 ; year:2024 ; pages:1-14 ; date:12.2024
Signal transduction and targeted therapy ; 9, Heft 1 (12.1.2024), 1-14, 12.2024
- Creator
-
Yu, Zhengyu
Li, Hexian
Lu, Qizhong
Zhang, Zongliang
Tong, Aiping
Niu, Ting
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41392-023-01702-2
- URN
-
urn:nbn:de:101:1-2024032210021159018241
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yu, Zhengyu
- Li, Hexian
- Lu, Qizhong
- Zhang, Zongliang
- Tong, Aiping
- Niu, Ting
- SpringerLink (Online service)
Other Objects (12)
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma
Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer
CAR-T cells in multiple myeloma: current status
Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies
Carborane Analogues of Fenoprofen Exhibit Improved Antitumor Activity
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Preclinical development of CD126 CAR-T cells with broad antitumor activity
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Superior anti-tumor efficacy of CD4⁺ CAR-T cells in hematological malignancies
CAR-T cell therapy in Multiple Myeloma: current status and future challenges
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma
Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer
CAR-T cells in multiple myeloma: current status
Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies
Carborane Analogues of Fenoprofen Exhibit Improved Antitumor Activity
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Preclinical development of CD126 CAR-T cells with broad antitumor activity
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Superior anti-tumor efficacy of CD4⁺ CAR-T cells in hematological malignancies
CAR-T cell therapy in Multiple Myeloma: current status and future challenges
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma
Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer
CAR-T cells in multiple myeloma: current status
Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies
Carborane Analogues of Fenoprofen Exhibit Improved Antitumor Activity
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Preclinical development of CD126 CAR-T cells with broad antitumor activity
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Superior anti-tumor efficacy of CD4⁺ CAR-T cells in hematological malignancies